Dear editor
Though there are several trials demonstrating noninferiority of novel oral anticoagulants (nOACs) versus previous standards of care for deep venous thrombosis/ pulmonary embolism, [1] [2] [3] [4] there are none including cerebral venous thrombosis (CVT). We surveyed Canadian neurologists and hematologists regarding use of nOACs for CVT.
Participants were recruited from two national email lists: Canadian Stroke Consortium (CSC) and Thrombosis Canada (TC). The survey consisted of 15 questions regarding patterns of practice for initial and maintenance anticoagulation for CVT, estimated annual case volume, and demographic information.
Twenty-nine of 113 from CSC and 22/70 from TC responded. Seventy percent used unfractionated heparin infusion as initial treatment of choice for CVT, 25% low-molecular-weight heparin (LMWH), 2% warfarin, and 2% nOACs. For maintenance anticoagulation, 76% used warfarin, 18% LMWH, and 6% nOACs. Thirty-one percent had used a nOAC for maintenance anticoagulation, while only 6% had started the medication as an initial treatment. Of those who used a nOAC, 4 (25%) used dabigatran, 14 (88%) rivaroxaban, and 7 (44%) apixaban. Those who had never used a nOAC cited a lack of evidence for this indication (n ¼ 29, 83%), concerns regarding medico-legal liability (n ¼ 8, 23%), lack of available reversal agents (n ¼ 4, 11%), and lack of provincial drug coverage (n ¼ 1, 3%). Specialists with 10 years of experience or more were most likely to prescribe nOACs for CVT (OR ¼ 5.43, 95% CI 1.29-22.9) ( Table 1) .
Potential biases include voluntarily participation and means of survey distribution. All but two respondents were from academic centers and responses may not reflect patterns of practice in the community. Our 28% response rate is consistent with other web-based physician surveys not employing unconditional incentives. 5 Treatment patterns amongst physicians for acute and maintenance anticoagulation are heterogenous and reflect the state of clinical equipoise regarding choice of anticoagulants for CVT. Our results suggest that a clinical trial demonstrating non-inferiority to warfarin for secondary prevention is likely to change clinical practice. 
